Top

Published in:

01-04-2015 | News item

Medsafe: intravitreal VEGF-A inhibitors can result in stroke

Published in: Reactions Weekly | Issue 1/2015

Excerpt

Intravitreal administration of vascular endothelial growth factor (VEGF)-A inhibitors − such as ranibizumab (Lucentis), bevacizumab (Avastin) and aflibercept (Eylea) − can result in stroke, and there may be a greater risk of stroke associated with bevacizumab over that with ranibizumab, according to a report from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). …

CARM is based in Dunedin and is contracted by the New Zealand Government to collect reports of suspected adverse reactions to medicines.

New Zealand Medicines and Medical Devices Safety Authority. Risk of Stroke with Ranibizumab (Lucentis), Bevacizumab (Avastin) and Aflibercept (Eylea), Administered by Intravitreal Injection. Prescriber Update 36: 9, No. 1, 5 Mar 2015. Available from: URL: http://www.medsafe.govt.nz/profs/PUArticles/March2015StrokeRiskIntravitrealInjection.htm

Title: Medsafe: intravitreal VEGF-A inhibitors can result in stroke
Publication date: 01-04-2015
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2015
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-015-9097-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Medsafe: intravitreal VEGF-A inhibitors can result in stroke

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Dasatinib/imatinib/interferon-α/nilotinib

Amphotericin B

Betaxolol/clonidine interaction

Iobenguane

Iodixanol

Tobramycin/dexamethasone